Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10
Latest Information Update: 28 Jul 2023
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AMLSG16-10
- 15 Jun 2023 Results assessing the prognostic impact of the MRD status in patients with FLT3-ITD+ acute myeloid leukemia combining intensive chemotherapy with midostaurin followed by midomaintenance, presented at the 28th Congress of the European Haematology Association.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2021 Results assessing NGS-based FLT3-ITD MRD assay and evaluation of prognostic impact of FLT3-ITD MRD monitoring in FLT3-ITD+ AML patients from this study presented at the 26th Congress of the European Haematology Association